Clinical Pre-screening Protocol for Ovarian Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Allarity Therapeutics
Study ID
NCT03877796
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Drug Response Predictor® (DRP) — DEVICE
    A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Study Details

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Key Dates

Start date
Apr 11, 2019
Status verified
Oct 2025
Primary completion
Sep 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Ovarian cancer patients
    with formalin-fixed paraffin-embedded (FFPE) tumor tissue available

Primary Outcome Measure

Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug [ Time Frame: up to 2 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215-
OU Health Stephenson Cancer CenterOklahoma CityOklahoma73104
Christine Pappaterra, RN
[email protected]
405-271-8707
Kathleen Moore, MD (PRINCIPAL_INVESTIGATOR)
Swedish Center for Research and InnovationSeattleWashington98122
Karina Sills
[email protected]
206-386-2227
Fernanda Baptista Musa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Dana-Farber Cancer Institute· Boston, MAOU Health Stephenson Cancer Center· Oklahoma City, OKSwedish Center for Research and Innovation· Seattle, WA

Related Studies